No Prescription |
 |
 | ||
|
Prescription Drugs 9 |
|
| ||
No Prescription » Prescription Drugs 9
HYDERGINE Generic Co Dergocrine Mesylate Hyzaar Forte Generic Losartan and Hydrochlorthiazide Hyzaar Generic Losartan and Hydrochlorthiazide Imdur Generic Isosorbide Mononitrate Isordil Generic isosorbide Dinitrate Itoprid Generic Itopride hydrochloride Januvia Generic Sitagliptin Phosphate Kamagra Oral Jelly Banana Flavor Viagra Kamagra Oral Jelly Grape Flavor Viagra KAMAGRA ORAL JELLY Mint Flav Viagra KAMAGRA ORAL JELLY Orange Flav Viagra Kamagra Oral Jelly Strawberry Flavor Viagra Kenacort Oral Paste Kenalog in Orabase Lamictal DC Generic Lamotrigine Lamisil Cream Generic Terbinafine Lamisil Derm Gel Generic Terbinafine Lamisil Jock Itch Generic Terbinafine Lamisil Once 4gm Generic Terbinafine Lamisil Spray Generic Terbinafine Lantus Solostar Lantus OptiClik Cartridge
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|